BMS and Kite Unveil CAR-T Successes in Lymphoma

Bristol Myers Squibb (BMS), which has several facilities in Washington state, is making significant advancements with Breyanzi, a CD19-directed CAR-T cell therapy as a second line of treatment for adults with B-cell lymphoma. At the American Society of Hematology meeting, BMS and Kite Pharma shared data that Breyanzi is showing better results than the current standard for care for adults with B-cell lymphoma.

READ THE STORY at BioSpace »